

CITATION REPORT

List of articles citing

A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment

DOI: 10.3109/15563650.2015.1110590
Clinical Toxicology, 2016, 54, 1-13.

Source: <https://exaly.com/paper-pdf/65702770/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
279	Case Series of Synthetic Cannabinoid Intoxication from One Toxicology Center. 2016 , 17, 290-4		62
278	Clinical and Pharmacological Investigation of Myotoxicity in Sri Lankan Russell's Viper (<i>Daboia russelii</i>) Envenoming. 2016 , 10, e0005172		17
277	Biosampling strategies for emerging drugs of abuse: towards the future of toxicological and forensic analysis. 2016 , 130, 202-219		39
276	Four analytically confirmed cases of use of third-generation synthetic cannabinoid receptor agonists incorporating an adamantyl group. <i>Clinical Toxicology</i> , 2016 , 54, 533-4	2.9	2
275	Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence. 2016 , 109, 254-269		22
274	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. 2016 , 34, 256-267		19
273	Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. <i>Clinical Toxicology</i> , 2016 , 54, 632-7	2.9	22
272	Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. <i>Clinical Toxicology</i> , 2016 , 54, 512-8	2.9	41
271	Human urinary metabolite pattern of a new synthetic cannabimimetic, methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate. 2016 , 34, 316-328		10
270	The Growing Problem of New Psychoactive Substances (NPS). 2017 , 32, 1-18		38
269	Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. 2016 , 15, 195-204		146
268	Leveraging allosterity to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. 2016 , 11, 1223-1237		15
267	Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized Addiction Team Be Useful? A Pilot Study. 2016 , 51, 544-551		12
266	Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation. 2016 , 12, 396-401		23
265	Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. 2016 , 7, 1241-54		157
264	Cannabis Use and Psychiatric Disorders: Implications for Mental Health and Addiction Treatment. 2016 , 3, 450-462		9
263	Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. 2016 , 88, 11476-11485		142

262	Identification and quantification of synthetic cannabinoids in "spice-like" herbal mixtures: Update of the German situation for the spring of 2016. 2016 , 269, 31-41		43
261	Synthetic cannabinoid poisoning: A growing health concern. 2016 , 46, 34-41		4
260	Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose. 2016 , 12, 335-340		32
259	NPS: Medical Consequences Associated with Their Intake. 2017 , 32, 351-380		21
258	Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. <i>Clinical Toxicology</i> , 2016 , 54, 638-43	2.9	41
257	[Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. 2016 , 30, 25-36		25
256	[Synthetic cannabinoids: A new addiction matrix]. 2017 , 46, 11-22		8
255	Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA. <i>Clinical Toxicology</i> , 2017 , 55, 193-195	2.9	16
254	New Psychoactive Substances. 2017 , 59-85		3
253	Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. <i>Clinical Toxicology</i> , 2017 , 55, 338-345	2.9	35
252	[Cannabis-induced disorders]. 2017 , 88, 311-325		4
251	Alterations of the hematologic cells in synthetic cannabinoid users. 2017 , 31,		10
250	Cannabinoids as hippocampal network administrators. 2017 , 124, 25-37		37
249	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. 2017 , 41, 573-610		96
248	JWH-122 Consumption Adverse Effects: A Case of Hallucinogen Persisting Perception Disorder Five-Year Follow-Up. <i>Journal of Psychoactive Drugs</i> , 2017 , 49, 262-265	3.6	8
247	Comparison of the discriminative stimulus and response rate effects of Δ^9 -tetrahydrocannabinol and synthetic cannabinoids in female and male rats. 2017 , 172, 51-59		27
246	The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre. <i>International Journal of Drug Policy</i> , 2017 , 43, 74-82	5.5	12
245	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. 2017 , 35, 252-262		7

244	Spice boys: an exploratory study around novel psychoactive substance use on a male acute ward. 2017 , 10, 97-104	2
243	Novel Psychoactive Substances and Trends of Abuse. 2017 , 40, 374-382	10
242	Synthetic Cannabinoid Use Among High School Seniors. 2017 , 140,	20
241	Marijuana and Breastfeeding: Applicability of the Current Literature to Clinical Practice. 2017 , 12, 582-596	22
240	The emerging threat of synthetic cannabinoids. 2017 , 48, 22-30	5
239	Synthetic Cannabis Analogues and Suicidal Behavior: Case Report. 2017 , 11, 408-410	8
238	Acute pain management in patients with drug dependence syndrome. 2017 , 2, e611	28
237	New Psychoactive Substances in Pediatric Patients. 2017 , 64, 1223-1241	5
236	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. 2017 , 107, e1-e12	184
235	Medicinal cannabis: A primer for nurses. 2017 , 47, 40-46	5
234	Emerging Drugs of Abuse: Synthetic Cannabinoids, Phenylethylamines (2C Drugs), and Synthetic Cathinones. 2017 , 18, 203-211	6
233	Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis. 2017 , 14, 9	18
232	Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use. 2017 , 26, 568-571	5
231	The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids. 2017 , 57, 297-304	29
230	Interpretation of Workplace Tests for Cannabinoids. 2017 , 13, 106-110	23
229	Understanding the Link Between Cannabinoids and Psychosis. 2017 , 101, 197-199	8
228	Focus on cannabinoids and synthetic cannabinoids. 2017 , 101, 220-229	62
227	Medical cannabis: Another piece in the mosaic of autoimmunity?. 2017 , 101, 230-238	28

226	Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. 2017 , 13, 52-60	54
225	A 15-year-old boy with acute onset abdominal pain and hypertension. 2017 , 22, 301-302	
224	Role of cannabis in cardiovascular disorders. 2017 , 9, 2079-2092	105
223	A Functional Platform for the Detection of JWH-073 as a Model for Synthetic Cannabinoids. 2018 , 5, 1253-1258	15
222	[Acute pain management in patients with drug dependence syndrome]. 2018 , 32, 131-138	
221	Efectos cardiovasculares debido al consumo de cannabinoides. 2018 , 25, 230-235	
220	Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service. <i>Annals of Clinical Biochemistry</i> , 2018 , 55, 673-678 ²²	30
219	A new cause of ischaemic priapism: Synthetic cannabinoids. 2018 , 50, e13013	3
218	Systematic review and meta-analysis of cannabinoids in palliative medicine. 2018 , 9, 220-234	55
217	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. 2018 , 36, 304-312	9
216	The public health evidence-base on novel psychoactive substance use: scoping review with narrative synthesis of selected bodies of evidence. 2018 , 40, e303-e319	48
215	The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. 2018 , 287, 59-69	21
214	The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. 2018 , 10, 1099	7
213	Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis. <i>International Journal of Drug Policy</i> , 2018 , 52, 87-96	5.5 141
212	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. 2018 , 365, 437-446	48
211	Synthetic Cannabinoid Exposure in Adolescents Presenting for Emergency Care. 2021 , 37, e13-e16	6
210	The dark cloud of recreational drugs and vaping. 2018 , 111, 145-148	16
209	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification. 2018 , 64, 346-354	15

208	Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. <i>Clinical Toxicology</i> , 2018 , 56, 404-411	2.9	34
207	Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. 2018 , 134, 82-91		24
206	Could serum S100B be a predictor of neuronal damage and clinical poor outcomes associated with the use of synthetic cannabinoids? S100B to predict neuronal damage of SC in the ED. 2018 , 36, 435-441		4
205	Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid System. 2018 , 5, 418-427		2
204	Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ^9 THC in Rats. 2018 , 12, 703		12
203	Nephrotoxicity of Lithium and Drugs of Abuse. 2018 , 304-339		
202	Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. 2018 , 28, 1289-1304		14
201	Epigenetic Effects of Drugs of Abuse. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	10
200	A Case of Opioid Overdose? Or Is It?. 2018 , 2, 633-639		2
199	A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 2018 , 242, 121-158		9
198	Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures. 2018 , 252, 3-49		23
197	Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. 2018 , 113, 1850-1861		5
196	Cannabis medicinal: una guía para enfermeras. 2018 , 35, 34-39		
195	New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh. 2018 , 84, 2303-2310		11
194	The Consumption of New Psychoactive Substances and Methamphetamine. 2018 , 115, 49-55		14
193	New and Emerging Illicit Psychoactive Substances. <i>Medical Clinics of North America</i> , 2018 , 102, 697-714	7	25
192	Repeated Exposure to the "Spice" Cannabinoid JWH-018 Induces Tolerance and Enhances Responsiveness to 5-HT Receptor Stimulation in Male Rats. <i>Frontiers in Psychiatry</i> , 2018 , 9, 55	5	17
191	Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. 2018 , 6, 162		70

190	Increased risk of hospital admission for ICD-9-CM psychotic episodes following admission for epilepsy. 2018 , 59, 1603-1611		7
189	Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. 2018 , 30, e13370		40
188	Acute myocardial infarction triggered by use of synthetic cannabis. 2018 , 31, 200-202		8
187	Fatal Poisonings Associated with New Psychoactive Substances. 2018 , 252, 495-541		28
186	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. 2018 , 252, 191-226		34
185	Acute appendicitis complicated by necrotizing fasciitis in a teenager. 2018 , 37, 77-82		3
184	Cannabinoids: from pot to lab. 2018 , 15, 1286-1295		34
183	Cannabinoids for the treatment of rheumatic diseases - where do we stand?. 2018 , 14, 488-498		34
182	Patterns of Acute Toxicity Associated with New Psychoactive Substances. 2018 , 252, 475-494		6
181	When and How to Treat Possible Cannabis Use Disorder. <i>Medical Clinics of North America</i> , 2018 , 102, 667-681	7	6
180	Unnatural Death among Treatment Seeking Substance Users in Singapore: A Retrospective Study. <i>International Journal of Environmental Research and Public Health</i> , 2019 , 16,	4.6	3
179	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB receptors. 2019 , 176, 4653-4665		25
178	Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity. 2019 , 144,		7
177	Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. 2019 , 11,		21
176	Positive and Negative Effects of Cannabis and Cannabinoids on Health. 2019 , 105, 1139-1147		74
175	In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and <i>Cunninghamella elegans</i> and their detection in urine samples. 2019 , 411, 3561-3579		10
174	Mono-/polyintoxication with 5F-ADB: A case series. 2019 , 301, e29-e37		12
173	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. 2019 , 201, 25-38		36

172	Recreational and Illicit Drugs Causing Seizures and Epilepsy. 2019 , 848-851	
171	Alcohol- and Toxin-Induced Seizures. 2019 , 852-862	
170	Cytotoxicity of the synthetic cannabinoids 5C-AKB48, 5F-MDMB-PINACA, ADB-CHMINACA, MDMB-CHMICA and NM-2201 in A549 and TR146 cell lines. 2019 , 37, 398-411	1
169	Adolescents and Drug Abuse: 21st Century Synthetic Substances. 2019 , 20, 17-24	5
168	Cannabinoids, interoception, and anxiety. 2019 , 180, 60-73	18
167	Review of the many faces of synthetic cannabinoid toxicities. 2019 , 9, 93-99	34
166	Riluzole blocks HU210-facilitated ventral tegmental long-term depression by enhancing glutamate uptake in astrocytes. 2019 , 704, 201-207	3
165	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. 2019 , 236, 2677-2685	17
164	What are the psychological effects of using synthetic cannabinoids? A systematic review. 2019 , 33, 271-283	24
163	Death cases involving certain new psychoactive substances: A review of the literature. 2019 , 298, 186-267	69
162	Neue psychoaktive Substanzen im Kontext der Post-mortem-Toxikologie. 2019 , 29, 51-63	1
161	New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. 2019 , 7, 109	52
160	Risk management strategies of synthetic cannabis users. 2019 , 19, 270-281	1
159	Spice, vulnerability, and victimization: Synthetic cannabinoids and interpersonal crime victimization among homeless adults. 2019 , 1-7	6
158	Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities. 2019 , 14, e02252736	
157	Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations. 2019 , 98, e17015	7
156	The Association Between Cannabinoids and Psychosis. 2019 , 127-155	5
155	Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. 2019 , 368, 146-156	12

154	Synthetic Cannabinoid Use. 2019 , 169-176		1
153	Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017. <i>Clinical Toxicology</i> , 2019 , 57, 282-286	2.9	34
152	Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?. 2019 , 40, 160-169		7
151	Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors. 2019 , 11, 501-511		45
150	Functional effects of synthetic cannabinoids versus Δ^9 THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. 2019 , 24, 414-425		12
149	Synthetic cannabinoid receptor agonists: classification and nomenclature. <i>Clinical Toxicology</i> , 2020 , 58, 82-98	2.9	37
148	Cannabis Use and the Risk for Psychosis and Affective Disorders. <i>Journal of Dual Diagnosis</i> , 2020 , 16, 22-42	2.4	42
147	Synthetic Cannabinoids (SCs) in Metaphors: a Metaphorical Analysis of User Experiences of Synthetic Cannabinoids in Two Countries. 2020 , 18, 160-176		2
146	Characteristics and circumstances of synthetic cannabinoid-related death. <i>Clinical Toxicology</i> , 2020 , 58, 368-374	2.9	25
145	Identification and Quantification of 5-Fluoro ADB and the 5-Fluoro ADB Ester Hydrolysis Metabolite in Postmortem Blood Samples by LC-MS/MS. 2020 , 44, 133-139		4
144	Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication. 2020 , 86, 429-436		12
143	Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States. 2020 , 207, 107810		4
142	An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides. <i>Clinical Toxicology</i> , 2019 , 1-8	2.9	15
141	Application of Biofunctionalized Magnetic Nanoparticles Based-Sensing in Abused Drugs Diagnostics. 2020 , 92, 1033-1040		22
140	Bites by snakes of lesser medical importance in a cohort of snakebite patients from rural Sri Lanka. 2020 , 187, 105-110		2
139	The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. 2020 ,		7
138	Marijuana and the Pediatric Population. 2020 , 146,		13
137	Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases. 2021 , 19, 1748-1758.e2		7

136	In-Vitro Neutralization of the Neurotoxicity of Coastal Taipan Venom by Australian Polyvalent Antivenom: The Window of Opportunity. 2020 , 12,	2	
135	Synthesis and Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. 2020 , 11, 4434-4446	15	
134	Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update. 2020 , 77, 1284-1335		
133	Critical Illness Secondary to Synthetic Cannabinoid Ingestion. 2020 , 3, e208516	7	
132	The Effects of Cannabis Use on the Development of Adolescents and Young Adults. 2020 , 2, 461-483	8	
131	Man vs. man-made marijuana: A case of drug-induced posterior reversible encephalopathy syndrome (PRES) due to K2, a synthetic cannabinoid (SCB). 2020 , 10, 361-364	2	
130	Sex and Gender Differences in the Effects of Novel Psychoactive Substances. 2020 , 10,	8	
129	New psychoactive substances: a review and updates. 2020 , 10, 2045125320967197	36	
128	The top 100 most cited articles on rhabdomyolysis: A bibliometric analysis. 2020 , 38, 1754-1759	6	
127	In vitro activity profiling of Cumyl-PEGACLONE variants at the CB receptor: Fluorination versus isomer exploration. 2020 , 12, 1336-1343	10	
126	Historical and Current Perspectives of Synthetic Marijuana: Critical Review. 2020 , 31, 85-91	0	
125	The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. 2020 , 50, 359-382	32	
124	Cannabis and multiple sclerosis. 2020 , 20, 849-854	9	
123	Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users. <i>Frontiers in Psychiatry</i> , 2020 , 11, 355	5	5
122	Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds. <i>International Journal of Drug Policy</i> , 2020 , 77, 102711	5.5	2
121	The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. 2020 , 35, e2727		12
120	Using Sesame Seed Oil to Preserve and Preconcentrate Cannabinoids for Paper Spray Mass Spectrometry. 2020 , 31, 675-684		4
119	Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model. 2020 , 11, 464		10

118	Designer drugs: mechanism of action and adverse effects. <i>Archives of Toxicology</i> , 2020 , 94, 1085-1133	5.8	57
117	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. 2020 , 193, 172918		3
116	Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. <i>Clinical Toxicology</i> , 2021 , 59, 472-479	2.9	5
115	The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA. 2021 , 13, 427-438		14
114	Disentangling the lasting effects of adolescent cannabinoid exposure. 2021 , 104, 110067		9
113	Broadly Neutralizing Synthetic Cannabinoid Vaccines. 2021 , 1, 31-40		4
112	A Literature Review of Cannabis and Myocardial Infarction-What Clinicians May Not Be Aware Of. 2021 , 3, 12-21		3
111	New/emerging psychoactive substances and associated psychopathological consequences. 2021 , 51, 30-42		28
110	Neurotoxicity of Exogenous Cannabinoids. 2021 , 1-31		
109	Neurotoxicology Emergencies. 2021 , 373-401		
108	Mortality involving New Psychoactive Substances across Europe, 2016-2017. 2021 , 1, 100016		0
107	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. 2021 , 1		3
106	Behavioral Effects of Developmental Exposure to JWH-018 in Wild-Type and Disrupted in Schizophrenia 1 () Mutant Zebrafish. 2021 , 11,		4
105	Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications. 2021 , 14,		4
104	The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. 2021 , 14, 10		2
103	Behavioral pharmacology of five novel synthetic cannabinoids. <i>Behavioural Pharmacology</i> , 2021 ,	2.4	0
102	Prevalence of cardiac arrhythmias in cannabis use disorder related hospitalizations in teenagers from 2003 to 2016 in the United States. 2021 , 23, 1302-1309		0
101	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. 2021 , 202, 173118		3

100	Symptoms of Intoxication and Withdrawal in a Sample of Egyptian Patients Using Synthetic Cannabinoids. 2021 , Publish Ahead of Print,		
99	Ecstasy and related drug consumption and the effect on emergency department resource use. 2021 ,		0
98	Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports. <i>Frontiers in Psychiatry</i> , 2021 , 12, 669921	5	0
97	Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. 2021 , 187, 108478		4
96	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB receptor activation assays-Part II: Structure activity relationship assessment via a β arrestin recruitment assay. 2021 , 13, 1402-1411		5
95	Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. 2021 , 44, 402-413		4
94	Comprehensive analytical and structural characteristics of methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA). 2021 , 39, 481-492		1
93	Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence. <i>Medical Cannabis and Cannabinoids</i> , 2021 , 4, 43-60	4.1	6
92	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. 2021 , 13, 1412-1429		6
91	Gastrointestinal manifestations of synthetic cannabinoids: a retrospective cohort study. 2021 , 21, 274		2
90	The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. 2021 , 3, 33		
89	The synthetic CB cannabinoid receptor selective agonists: Putative medical uses and their legalization. 2021 , 110, 110301		0
88	Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study. 2021 , 12, 705643		0
87	Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. 2021 , 61 Suppl 2, S37-S52		4
86	Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. 2021 , 1		1
85	Seizures in patients with kidney diseases: a neglected problem?. 2021 ,		1
84	'Synthetic cannabis': A dangerous misnomer. <i>International Journal of Drug Policy</i> , 2021 , 98, 103396	5.5	2
83	Synthetic cannabinoids (SC). 2022 , 415-446		

82	Therapeutic potential of cannabinoids in combination cancer therapy. 2021 , 79, 100774		9
81	New Drugs of Abuse and Cardiovascular Function. 2020 , 843-868		2
80	Cannabis. 2019 , 143-175		0
79	Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis. <i>International Journal of Drug Policy</i> , 2017 , 44, 121-129	5.5	23
78	Exploring the Relationships between Sexual Orientation and Gender Identity and Youth Synthetic Cannabinoid Use. <i>Substance Use and Misuse</i> , 2021 , 56, 327-332	2.2	2
77	Translational models of cannabinoid vapor exposure in laboratory animals. <i>Behavioural Pharmacology</i> , 2020 ,	2.4	9
76	General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain</i> , 2021 , 162, S80-S96	8	16
75	The Clinical Conundrum of Cannabis: Current Practices and Recommendations for Transplant Clinicians: An Opinion of the Immunology/Transplantation PRN of the American College of Clinical Pharmacy. <i>Transplantation</i> , 2021 , 105, 291-299	1.8	4
74	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids.		2
73	Pseudo-Wellens' syndrome secondary to concurrent cannabis and phencyclidine intoxication. <i>BMJ Case Reports</i> , 2018 , 2018,	0.9	5
72	Cannabis, cannabinoids, and health. <i>Dialogues in Clinical Neuroscience</i> , 2017 , 19, 309-316	5.7	83
71	The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. <i>Public Health Research</i> , 2017 , 5, 1-138	1.7	10
70	Evidence for public health on novel psychoactive substance use: a mixed-methods study. <i>Public Health Research</i> , 2019 , 7, 1-150	1.7	4
69	Acute Rhabdomyolysis Following Synthetic Cannabinoid Ingestion. <i>North American Journal of Medical Sciences</i> , 2016 , 8, 256-8	0	13
68	The switch from one substance-of-abuse to another: illicit drug substitution behaviors in a sample of high-risk drug users. <i>PeerJ</i> , 2020 , 8, e9461	3.1	2
67	Arrhythmia-related Hospitalization and Comorbid Cannabis Use Disorder: Trend Analysis in US Hospitals (2010-2014). <i>Cureus</i> , 2019 , 11, e5607	1.2	10
66	Synthetic Cannabinoid Induced acute Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Report and Review of Literature. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016 , 10, OD31-2	0	4
65	The structure of acute chemical poisoning in patients with HIV infection in the emergency hospital. <i>Narkologija</i> , 2018 , 3-13	0	

64	The structure of acute chemical poisoning in patients with HIV infection in the emergency hospital. <i>Narkologija</i> , 2018 , 3-13	0	2
63	Cannabiskonsum zum Freizeitgebrauch. 2019 , 65-264		1
62	Disseminated Intravascular Coagulopathy Secondary to Unintentional Brodifacoum Poisoning via Synthetic Marijuana. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019 , 8, 40-43	0.8	
61	Modulation of Human T-type Calcium Channels by Synthetic Cannabinoid Receptor Agonists in vitro.		
60	Rhabdomyolysis associated with laboratory-confirmed FUB-AMB use. 2020 , 281-282		
59	Association between gestational cannabis exposure and maternal, perinatal, placental, and childhood outcomes. <i>Journal of Developmental Origins of Health and Disease</i> , 2021 , 12, 694-703	2.4	1
58	Phenotype-based screening of synthetic cannabinoids in a Dravet Syndrome zebrafish model.		
57	Using sesame seed oil to preserve and concentrate cannabinoids for paper spray mass spectrometry. <i>Comprehensive Analytical Chemistry</i> , 2020 , 90, 367-395	1.9	0
56	Poisoning by drugs and chemicals. 2020 , 1725-1777		
55	Synthetic drugs of abuse. <i>Advances in Clinical Chemistry</i> , 2021 , 103, 191-214	5.8	5
54	New Drugs of Abuse and Cardiovascular Function. 2020 , 1-27		
53	Neue psychoaktive Substanzen. <i>Notfall Und Rettungsmedizin</i> , 1	0.4	
52	Behavioral effects of developmental exposure to JWH-018 in wild type and disrupted in schizophrenia 1 (disc1) mutant zebrafish.		
51	Synthetic Cannabinoids-"Spice" Can Induce a Psychosis: A Brief Review. <i>Innovations in Clinical Neuroscience</i> , 2019 , 16, 31-32	1	13
50	Nephrotoxins. 2021 , 1-24		
49	Clinical Approaches to Cannabis: A Narrative Review. <i>Medical Clinics of North America</i> , 2022 , 106, 131-157		0
48	Effects of Cannabis on Cardiovascular System: The Good, the Bad, and the Many Unknowns.. <i>Medical Cannabis and Cannabinoids</i> , 2021 , 4, 75-85	4.1	1
47	Fourth generation of synthetic cannabinoid receptor agonists: A review on the latest insights. <i>Current Pharmaceutical Design</i> , 2021 ,	3.3	3

46	Lethal case of myocardial ischemia following overdose of the synthetic cannabinoid ADB-FUBINACA.. <i>Legal Medicine</i> , 2021 , 54, 102004	1.9	1
45	Catatonic Episodes Related to Substance Use: A Cross-Sectional Study Using Electronic Healthcare Records.. <i>Journal of Dual Diagnosis</i> , 2022 , 1-7	2.4	0
44	Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: a Review of the Clinical and Pre-clinical Data.. <i>Current Pain and Headache Reports</i> , 2022 , 26, 103	4.2	
43	Clinical pattern of synthetic cannabinoids users in Upper Egypt: cross-sectional study. <i>Middle East Current Psychiatry</i> , 2022 , 29,	2.4	
42	Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?. <i>Cells</i> , 2022 , 11,	7.9	2
41	Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.. <i>Medicines (Basel, Switzerland)</i> , 2022 , 9,	4.1	2
40	Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression.. <i>Cannabis and Cannabinoid Research</i> , 2021 ,	4.6	0
39	Addictions and Substance Misuse. 451-536		
38	Analytical findings in a non-fatal intoxication with the synthetic cannabinoid 5F-ADB (5F-MDMB-PINACA): a case report.. <i>International Journal of Legal Medicine</i> , 2021 , 136, 577	3.1	2
37	Substance-Induced Psychoses: An Updated Literature Review.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 694863	5	1
36	An Update on the Implications of New Psychoactive Substances in Public Health.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	2
35	Association between cannabis use and suicidal behavior: A systematic review of cohort studies.. <i>Psychiatry Research</i> , 2022 , 312, 114555	9.9	0
34	Table_1.xlsx. 2020 ,		
33	Cannabinoids in rheumatology: Friend, foe or a bystander?. <i>Musculoskeletal Care</i> , 2022 ,	1.6	
32	A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence. <i>Frontiers in Psychiatry</i> , 2022 , 13,	5	1
31	Ɖpice Was Made, by the Devil Himself—A Thematic Analysis of the Experience of an Addiction to Synthetic Cannabinoids. <i>Journal of Psychoactive Drugs</i> , 1-9	3.6	
30	Rapid biosensor development using plant hormone receptors as reprogrammable scaffolds. <i>Nature Biotechnology</i> ,	44.5	2
29	Biochip Array Technology for new psychoactive substances detection in biological samples: evaluation of the specificity of the Randox Evidence Investigator[®]. <i>Annals of Clinical Biochemistry</i> , 000456322211117	2.2	1

28	Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans. <i>International Journal of Drug Policy</i> , 2022 , 106, 103756	5.5	1
27	Cannabinoids. <i>Advances in Neurotoxicology</i> , 2022 ,	1.6	
26	Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases. <i>Archives of Toxicology</i> ,	5.8	0
25	In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamic and Pharmacokinetic Studies in Mice. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 8030	6.3	0
24	Pediatric Brain on Cannabinoids: Adverse Effects of Cannabinoid Products in Children and Adolescents.		
23	Synthetic Cannabinoids: A Pharmacological and Toxicological Overview. 2023 , 63,		1
22	Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.		
21	Metabolism of ADB-4en-PINACA in Zebrafish and Rat Liver Microsomes Determined by Liquid ChromatographyHigh Resolution Mass Spectrometry. 2022 , 77, 1036-1046		
20	Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019. 1-5		0
19	Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers. 2022 , 10, 1936		0
18	Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England. 1-5		0
17	Nephrotoxins. 2022 , 1653-1676		0
16	A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects. Volume 11, 55-66		0
15	Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring.		2
14	Öcuk acil hastalarıda yasa dışı ilaçların LC-MS/MS kullanılarak değerlendirilmesi.		0
13	In vitro metabolic fate of the synthetic cannabinoid receptor agonists (quinolin-8-yl 4-methyl-3-(morpholine-4-sulfonyl)benzoate [QMMSB]) and (quinolin-8-yl 4-methyl-3-((propan-2-yl)sulfamoyl)benzoate [QMIPSB]) including isozyme mapping and carboxylesterases activity testing.		0
12	Acute Hepatic Injury Associated with Acute Administration of Synthetic Cannabinoid XLR-11 in Mouse Animal Model. 2022 , 10, 668		0
11	Cannabinoids and Their Role in Chronic Pain Treatment: Current Concepts and a Comprehensive Review. 2022 , 10,		0

- 10 Metabolism studies of 4*α*-CUMYL-PINACA, 4*β*-CUMYL-5F-PINACA, and 4*β*-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis.. ○
- 9 Neurotoxicity of Exogenous Cannabinoids. **2022**, 1323-1353 ○
- 8 The Old and the New: Cardiovascular and Respiratory Alterations Induced by Acute JWH-018 Administration Compared to Δ^9 -THC. Preclinical Study in Mice. **2023**, 24, 1631 1
- 7 Approach to toxicological deaths. **2023**, 339-374 ○
- 6 First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation. **2023**, 320, 115053 ○
- 5 New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions. **2023**, 2023, 1-36 ○
- 4 Psychomotor performances relevant for driving under the combined effect of ethanol and synthetic cannabinoids: A systematic review. 14, ○
- 3 Using in vitro receptor activity studies of synthetic cannabinoids to support the risk assessment of new psychoactive substances -a Swedish strategy to protect Public Health from harm. **2023**, 111691 ○
- 2 The endocannabinoid system and breathing. 17, ○
- 1 Acute Cardiovascular and Cardiorespiratory Effects of JWH-018 in Awake and Freely Moving Mice: Mechanism of Action and Possible Antidotal Interventions?. **2023**, 24, 7515 ○